Assertio Earnings Reports

Assertio reported first quarter 2025 total net product sales of $26.0 million, in line with their 2025 outlook. The company achieved substantial progress on its business strategy, including settling legal matters, simplifying its corporate structure, and focusing on growth assets like Rolvedon and Sympazan. Net loss was $13.5 million, and adjusted EBITDA was $0.2 million.

Assertio's Q4 2024 net product sales totaled $29.6 million, reflecting a decline from the prior year. Gross margin fell to 61% due to higher inventory write-downs. The company reported a GAAP net loss of $10.5 million, while adjusted EPS was -$0.03. Free cash flow remained positive at $11.5 million.

Assertio Holdings reported solid performance in Q3 2024, with Rolvedon establishing itself as the lead asset, contributing to a total net product sales of $28.7 million. The company is implementing new strategies for Sympazan and maximizing the value of Indocin while evaluating new growth opportunities.

Assertio Holdings reported second quarter net product sales of $30.7 million. Rolvedon's growth continued with $15.1 million in net product sales. The company generated $7.4 million in cash flow from operations, and cash and short-term investments increased to $88.4 million.

Assertio reported first quarter net product sales of $31.9 million, driven by Rolvedon growth, which reached $14.5 million. The company generated $7.5 million in cash flow from operations, increasing cash to $80.7 million. They reiterated their 2024 guidance for net product sales of $110 million to $125 million and adjusted EBITDA of $20 million to $30 million.

Assertio Holdings, Inc. reported Q4 net product sales of $32.5 million and cash flow from operations of $5.7 million. The company is providing guidance for 2024, targeting net product sales of $110 million to $125 million and adjusted EBITDA of $20 million to $30 million.

Assertio Holdings reported disappointing Q3 2023 financial results, primarily due to the loss of Indocin exclusivity and lower-than-expected Rolvedon results. Net product sales increased slightly year-over-year, but the company experienced a significant net loss due to a charge for loss on impairment of intangible assets. Despite these challenges, the non-personal platform continues to drive growth for other assets like Sympazan and Otrexup.

Assertio Holdings reported a strong second quarter with a 13% increase in net product sales, reaching $40.1 million. The acquisition of Spectrum Pharmaceuticals is expected to enhance the company's revenue base and commercial capabilities. The company generated $18.6 million in cash flow from operations.

Assertio Holdings, Inc. reported a strong first quarter with an 18% increase in net product sales, driven by Indocin and Sympazan. The company is raising its full-year net product sales and adjusted EBITDA outlook. They also announced the acquisition of Spectrum Pharmaceuticals.

Assertio Holdings, Inc. reported strong financial results for the fourth quarter and full year ended December 31, 2022. Net product sales increased by 55% in the fourth quarter, and GAAP net income saw a substantial increase due to a tax benefit. The company's strategic actions and acquisitions contributed to the positive change in the business.

Assertio Holdings, Inc. reported a 32% year-over-year increase in net product sales to $34.3 million for the third quarter of 2022. GAAP net income increased to $4.2 million, and adjusted EBITDA increased to $21.4 million. The company has raised its full year guidance for net product sales and adjusted EBITDA.

Assertio Holdings, Inc. reported financial results for the first quarter ended March 31, 2022, with net product sales of $35.5 million, a 37% increase compared to the prior year quarter. The company's net income was $9.1 million, a 99% increase compared to the prior year quarter. Due to the strength of the results to date and the confidence we have in the outlook of our business, we are raising the full year non-GAAP adjusted EBITDA guidance.